Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dexverapamil to overcome epirubicin resistance in advanced breast cancer.
Thürlimann B, Kröger N, Greiner J, Mross K, Schüller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H, et al. Thürlimann B, et al. Among authors: schumacher k. J Cancer Res Clin Oncol. 1995;121 Suppl 3:R3-6. doi: 10.1007/BF02351063. J Cancer Res Clin Oncol. 1995. PMID: 8698740 Clinical Trial.
Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy--a pilot study of the German Myeloma Treatment Group (GMTG).
Peest D, Deicher H, Fett W, Harms P, Braun HJ, Planker M, Kindler U, Klinkenstein C, Schäfer E, Schumacher K, Siecke H. Peest D, et al. Among authors: schumacher k. Eur J Cancer. 1996 Nov;32A(12):2053-7. doi: 10.1016/s0959-8049(96)00228-6. Eur J Cancer. 1996. PMID: 9014744 Clinical Trial.
Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, Neeser E, von Ingersleben G, Hossfeld D, Waldmann R. Heidemann E, et al. Among authors: schumacher k. Onkologie. 1990 Feb;13(1):24-7. doi: 10.1159/000216714. Onkologie. 1990. PMID: 2186320 Clinical Trial.
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Müller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Köppler H, Parwaresch R, Pfreundschuh M, Havemann K. Kaiser U, et al. Among authors: schumacher k. J Clin Oncol. 2002 Nov 15;20(22):4413-9. doi: 10.1200/JCO.2002.07.075. J Clin Oncol. 2002. PMID: 12431962 Clinical Trial.
VBAMDex chemotherapy in advanced multiple myeloma.
Peest D, Schmoll HJ, Schedel I, Glück S, Schumacher K, Deicher H. Peest D, et al. Among authors: schumacher k. Eur J Haematol. 1988 Mar;40(3):245-9. doi: 10.1111/j.1600-0609.1988.tb00831.x. Eur J Haematol. 1988. PMID: 3356240
762 results